Title: Reduced survival in COPD patients who received long-term oxygen therapy without meeting prescription criteria: a preliminary study

Authors: François Alexandre¹, Alain Varray², Yannick Stéphan², Maurice Hayot³, Nelly Héraud¹

Affiliations:

¹Cliniques du Souffle, Service Recherche, Groupe 5 Santé, Lodève, France

²Euromov, Univ. Montpellier, Montpellier, France

³PhyMedExp, Univ. Montpellier, INSERM, CNRS, CHU de Montpellier, France

Corresponding author:

François Alexandre

Cliniques du Souffle, Groupe 5 Santé

800 avenue Joseph Vallot, 34700 Lodève, France

francois.alexandre@5-sante.fr

Abstract:

Background: Randomized clinical trials have provided clear evidence that long-term oxygen therapy (LTOT) increases life expectancy in severely hypoxemic COPD patients. However, in real-life settings, in global COPD cohorts, a paradoxical 2-3-fold increased risk of death has been reported in patients under LTOT. This discrepancy could be explained by a subgroup of patients under LTOT who do not meet the current guidelines and for whom LTOT would be associated with poor prognosis. This retrospective study of a global COPD cohort therefore sought to: (1) determine if a subgroup of patients under LTOT without severe hypoxemia could be distinguished, and (2) compare the mortality risk according to hypoxemia severity and LTOT prescription.

Method: The sample was taken from a database (NCT02055885) on 191 stable COPD patients (age: 65.1 ± 9.8 years, 85 women) admitted for a pulmonary rehabilitation program between 2009 and 2012 and followed until 1 January 2018. Uni- and multivariate Cox proportional hazard ratio (HR) models were used to examine the associations between clinical characteristics (age, sex, blood gases, etc.), LTOT according to PaO₂ level, and mortality.

Results: Forty patients (21%) were under LTOT at PR entry despite not meeting the O₂ prescription criteria. Patients under LTOT had a nearly 2-fold higher mortality risk adjusted by covariates ($HR_{multivariate}=1.83$; $p=0.009$). Furthermore, the higher mortality risk under LTOT was specific to the patients under LTOT without severe hypoxemia ($HR_{multivariate}=2.39$; $p=0.04$).

Conclusion: The association between LTOT and mortality might be attributed to a subgroup under LTOT despite not/no longer meeting the LTOT criteria. Further studies are needed to identify the physiological basis of this phenomenon.

Contributors: FA and NH conceived and designed the study; FA and NH analyzed the data; AV, YS and MH provided statistical support and assisted with data analysis; FA drafted the first version of the manuscript. All co-authors read and commented on earlier versions of the manuscript.

Funding: None declared.

Competing interests: None declared.

1 Introduction

2 Long-term oxygen therapy (LTOT) is a proven, well-established therapy to increase life
 3 expectancy in chronic obstructive pulmonary disease (COPD) patients with severe
 4 hypoxemia. The first data on LTOT's effects indicated an almost 2-fold increase in survival
 5 rates in severely hypoxemic COPD patients undergoing LTOT ($\text{PaO}_2 \leq 55$ mmHg, or 59
 6 mmHg with concurrent polycythemia or signs of right-sided heart failure or pulmonary
 7 hypertension)^{1, 2}. While the benefits of O_2 therapy for severely hypoxemic COPD patients are
 8 indisputable, the benefits for the overall COPD population remain unclear. Indeed, a
 9 paradoxical association has been reported in global COPD cohorts that include all stages of
 10 hypoxemia, with a 2-3-fold increased risk of death in those undergoing LTOT³⁻⁵. This
 11 association remained even after controlling for disease severity (FEV_1), age, BMI, and
 12 exacerbations³⁻⁵.

13 Thus, despite LTOT's substantial clinical impact, its association with a higher risk of death
 14 remains unclear as it has not been investigated. Yet if LTOT slows the mortality rate in some
 15 types of patients (i.e., severely hypoxemic) but shows an inverse association with the
 16 mortality risk in the overall COPD population, this indicates another subgroup of patients who
 17 do not meet the current guidelines for LTOT prescription and for whom O_2 therapy is
 18 associated with deleterious consequences. This study of a global COPD cohort therefore
 19 sought to: (1) determine whether a subgroup of patients under LTOT without severe
 20 hypoxemia could be distinguished, and (2) compare the mortality risk according to the
 21 severity of hypoxemia and LTOT prescription.

22 Methods

23 The sample was taken from an unpublished database (NCT02055885) on 191 stable COPD
 24 patients (mean age: 65.1±9.8 years, 85 women) who were admitted to the Cliniques du
 25 Souffle in France between 2009 and 2012 for a pulmonary rehabilitation program (PR) and
 26 followed until 1 January 2018. Blood gases were evaluated on the day patients entered PR, at
 27 rest and while breathing room air. No LTOT indications noted by the physician-prescriber
 28 were modified, but potential differences with LTOT guidelines were reported by the PR
 29 physician in the patient's medical record. The patients were categorized into 4 groups
 30 according to their resting PaO₂ on air (≤59 mmHg or >59 mmHg, labeled as severe or not-
 31 severe hypoxemia: SH or nSH) and LTOT prescription (LTOT or nLTOT):

- 32 • nSH-LTOT (PaO₂>59 mmHg and LTOT)
- 33 • nSH-nLTOT (PaO₂>59 mmHg and no LTOT)
- 34 • SH-nLTOT (PaO₂≤59 mmHg and no LTOT)
- 35 • SH-LTOT (PaO₂≤59 mmHg and LTOT)

36 The baseline clinical characteristics of the 4 groups were compared using ANOVA and HSD
 37 post-hoc tests. Time to event was defined as the time (in months) from entry to PR to the
 38 month of death or the month when follow-up ended (i.e., 1 January 2018). Univariate and
 39 multivariate Cox proportional hazard ratio (HR) models were used to examine the
 40 associations between clinical characteristics (age, sex, body mass index: BMI, FEV₁,
 41 FEV₁/FVC, PaO₂, PaCO₂ and 6-minute walking distance: 6MWD), LTOT according to PaO₂
 42 level, and mortality. Using the means of these covariates in the Cox regression model, the
 43 estimated survival functions were calculated for each subgroup. Statistical analyses were
 44 conducted with Statistica Software (Statsoft, V13.0, OK, USA). The significance level was set
 45 at p≤0.05.

46 Results

47 The median follow-up was 84.7 [Q1: 1.1; Q3: 108.7] months. Descriptive statistics of the
 48 population are provided in Table 1. Forty patients were under LTOT (nSH-LTOT group; 21%
 49 of the study sample) at PR entry despite not meeting the O₂ prescription criteria. First, we
 50 confirmed that the patients under LTOT had a nearly 2-fold higher mortality risk adjusted by
 51 covariates ($HR_{\text{multivariate}}=1.83$; 95% confidence intervals: CI=1.16-2.9; $p=0.009$, data not
 52 presented in table). Furthermore, we found that the higher mortality risk under LTOT was
 53 specific to the patients under LTOT without severe hypoxemia (nSH-LTOT group; Table 2).
 54 In both univariate and multivariate analyses, these patients had an almost 2.5-fold higher
 55 mortality risk than the patients without severe hypoxemia and without LTOT
 56 ($HR_{\text{multivariate}}=2.39$; 95% CI=1.42-4.03; $p=0.04$). Figure 1 displays the adjusted survival curves
 57 for each subgroup.

58 Discussion

59 In line with previous studies, this study showed a higher mortality risk in patients under
60 LTOT in a general COPD population with various hypoxemia severities³⁻⁵. In addition, we
61 specifically found a nearly 2.5-fold higher mortality risk in the patients under LTOT without
62 severe hypoxemia ($\text{PaO}_2 > 59$ mmHg). Therefore, our data shed new light on the paradoxical
63 association between LTOT and mortality in a global COPD cohort, which might be attributed
64 to a subgroup of patients receiving LTOT despite not/no longer meeting the LTOT criteria.

65 Past research has indicated that COPD patients with $\text{PaO}_2 > 59$ mmHg are sometimes
66 prescribed LTOT despite not meeting the indication criteria⁶. This inappropriate prescription
67 has been ascribed to insufficient adherence to guidelines by prescribing physicians⁷. For
68 example, one study found that 18.5% of COPD patients undergoing LTOT had resting PaO_2
69 on air > 60 mmHg at the time of prescription⁸. LTOT started in unstable patients after
70 hospitalization and poor treatment re-evaluation are also worth considering: ~40% of patients
71 who meet the hypoxemia criteria at a given time are no longer hypoxemic 1-3 months later^{1, 9}.
72 Yet, most patients are never re-evaluated, whether in clinical practice⁷ or longitudinal clinical
73 trials¹⁰.

74 This study has limitations. First, the sample size was too small to draw definitive conclusions.
75 Furthermore, comorbidities, adherence to LTOT and exacerbations could not be retrieved.
76 Importantly, although not controlled in this study, the paradoxical association between LTOT
77 and mortality was previously observed regardless of exacerbations³.

78 Conclusion

79 This research suggests a plausible explanatory hypothesis about the paradoxical association
 80 between mortality risk and LTOT in a general COPD cohort with various hypoxemia
 81 severities. In the study, the higher mortality risk under LTOT was specifically found in
 82 patients without severe hypoxemia and thus not meeting the current guidelines for LTOT
 83 prescription (mean $\text{PaO}_2=69.9$ mmHg). Larger controlled prospective clinical trials with O_2
 84 supplementation vs. non-supplementation in the overall COPD population are warranted to
 85 identify a physiological explanation for this phenomenon and to rule out (or not) any causal
 86 relationship.

87 References

- 88 1. [No authors listed]. Continuous or nocturnal oxygen therapy in hypoxemic chronic
89 obstructive lung disease. Nocturnal Oxygen Therapy Trial Group. *Ann Intern Med*. 1980;93:391-8.
- 90 2. [No authors listed]. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale
91 complicating chronic bronchitis. Report of the Medical Research Council Party. *Lancet*. 1981;1:681-5.
- 92 3. Hjalmsen A, Brenn T, Risberg MJ, et al. Retrospective survival in elderly COPD patients
93 receiving pulmonary rehabilitation; a study including maintenance rehabilitation. *BMC research*
94 *notes*. 2014;7(1):210.
- 95 4. Houchen-Woloff L, Williams JE, Green RH, et al. Survival following pulmonary rehabilitation
96 in patients with COPD: the effect of program completion and change in incremental shuttle walking
97 test distance. *International journal of chronic obstructive pulmonary disease*. 2018;13:37.
- 98 5. Yohannes AM, Baldwin RC, Connolly M. Mortality predictors in disabling chronic obstructive
99 pulmonary disease in old age. *Age and ageing*. 2002;31(2):137-40.
- 100 6. Pavlov N, Haynes AG, Stucki A, et al. Long-term oxygen therapy in COPD patients: population-
101 based cohort study on mortality. *International journal of chronic obstructive pulmonary disease*.
102 2018;13:979.
- 103 7. Rous MRG. Long-term oxygen therapy: are we prescribing appropriately? *International*
104 *journal of chronic obstructive pulmonary disease*. 2008;3(2):231.
- 105 8. Veale D, Chailleux E, Taytard A, et al. Characteristics and survival of patients prescribed long-
106 term oxygen therapy outside prescription guidelines. *European Respiratory Journal*. 1998;12(4):780-
107 4.
- 108 9. Levi-Valensi P, Weitzenblum E, Pedinielli J-L, et al. Three-month follow-up of arterial blood
109 gas determinations in candidates for long-term oxygen therapy: a multicentric study. *American*
110 *Review of Respiratory Disease*. 1986;133(4):547-51.
- 111 10. Ekström M, Ringbaek T. Which patients with moderate hypoxemia benefit from long-term
112 oxygen therapy? Ways forward. *International journal of chronic obstructive pulmonary disease*.
113 2018;13:231

Tables

Table 1. Baseline characteristics of the study subjects.

	nSH-LTOT (G1)	nSH-nLTOT (G2)	SH-LTOT (G3)	SH-nLTOT (G4)	ANOVA p-value	Significant post-hoc tests (p<0.05)
n	40	112	22	17		
Sex (M/F)	24/16	69/43	14/8	9/8		
Age (years)	67.2 (10)	65.7 (10)	62.1 (8)	61.7 (8)	0.11	
Height (cm)	166 (10)	166 (10)	169 (10)	165 (8)	0.52	
BMI	25.6 (6)	25.5 (6.9)	25.4 (6)	31.9 (12)	0.007	G4 vs G1, G2 & G3
FEV ₁ (L)	0.84 (0.4)	1.16 (0.5)	1.04 (0.6)	1.1 (0.6)	0.005	G1 vs G2
FEV ₁ (%pred)	35.3 (15)	45.7 (19)	37.4 (24)	41.6 (20)	0.02	G1 vs G2
FEV ₁ /FVC	0.45 (0.16)	0.5 (0.15)	0.42 (0.15)	0.44 (0.16)	0.07	
PaO ₂ (mmHg)	69.9 (11)	68.8 (8)	53.3 (4)	55.3 (3)	<0.001	G2 vs G3 & G4
PaCO ₂ (mmHg)	43.3 (7)	39.1 (7)	43.1 (7)	44.3 (8)	<0.001	G2 vs G1 & G4
6MWD (m)	323 (121)	397 (116)	384 (116)	398 (87)	0.007	G1 vs G2

BMI: body mass index; FEV₁: forced expiratory volume in 1 second; FVC: forced vital capacity; 6MWD: 6-minute walking distance; %pred: % of predicted values, nSH-LTOT group: LTOT with resting PaO₂ on air>59 mmHg, nSH-nLTOT group: no LTOT with PaO₂>59 mmHg, SH-LTOT group: LTOT with PaO₂≤59 mmHg, SH-nLTOT group: no LTOT with PaO₂≤59 mmHg. Values are mean ± SD.

122 **Table 2. Cox proportional hazard ratio analysis predicting mortality risk**

	Univariate			Multivariate		
	Hazard ratio	95% CI	p	Hazard ratio	95% CI	p
Sex						
Male	1.24	0.82-1.88	0.3	1.32	0.8-2.16	0.28
Female	1.0 (ref.)			1.0 (ref.)		
Age (years)	1.04	1.0-1.06	<0.001	1.04	1.01-1.06	0.004
BMI	0.96	0.93-0.99	0.009	0.94	0.91-0.98	0.002
FEV ₁ (L)	0.99	0.97-1.0	0.02	1.4	0.72-2.71	0.32
FEV ₁ /FVC	0.99	0.97-1.0	0.04	0.99	0.97-1.0	0.18
PaO ₂ (mmHg)	1.01	0.99-1.03	0.25	0.99	0.97-1.02	0.65
PaCO ₂ (mmHg)	1.06	1.03-1.09	<0.001	1.03	1.0-1.07	0.08
6MWD (m)	0.99	0.99-1.0	<0.001	0.99	0.99-1.0	<0.001
LTOT according to PaO ₂ level						
nSH-LTOT	3.0	1.89-4.78	<0.001	2.39	1.42-4.02	0.04
nSH-nLTOT	1.0 (ref.)			1.0 (ref.)		
SH-LTOT	1.62	0.61-4.27	0.65	1.21	0.44-3.29	0.63
SH-nLTOT	1.17	0.55-2.49	0.44	1.66	0.69-3.95	0.77

123 BMI: body mass index; FEV₁: forced expiratory volume in 1 second; FVC: forced vital capacity;
124 6MWD: 6-minute walking distance; nSH-LTOT group: LTOT with resting PaO₂ on air >59 mmHg, nSH-
125 nLTOT group: no LTOT with PaO₂ >59 mmHg, SH-LTOT group: LTOT with PaO₂ ≤59 mmHg, SH-
126 nLTOT group: no LTOT with PaO₂ ≤59 mmHg.
127
128

129 Figure

130

131

132 Figure 1: Survival curves in the 4 groups adjusted by age, sex, BMI, FEV1, FEV1/FVC, PaO₂, PaCO₂
133 and 6MWT distance. nSH-LTOT group: LTOT with resting PaO₂ on air >59 mmHg, nSH-nLTOT group:
134 no LTOT with PaO₂ >59 mmHg, SH-LTOT group: LTOT with PaO₂ ≤59 mmHg, SH-nLTOT group: no
135 LTOT with PaO₂ ≤59 mmHg.